These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29341824)

  • 21. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats.
    Liu C; Hu MY; Zhang M; Li F; Li J; Zhang J; Li Y; Guo HF; Xu P; Liu L; Liu XD
    Metabolism; 2014 Oct; 63(10):1342-51. PubMed ID: 25060691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced postprandial glucagon-like peptide-1 secretion during obesity development has a protective role against glucose intolerance induction in rats.
    Pinyo J; Hira T; Hara H
    Br J Nutr; 2019 Aug; 122(4):411-422. PubMed ID: 31352909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of High Fat Diets and Liver Peptidase Activity in the Development of Obesity and Insulin Resistance in Wistar Rats.
    Domínguez-Vías G; Segarra AB; Ramírez-Sánchez M; Prieto I
    Nutrients; 2020 Feb; 12(3):. PubMed ID: 32121057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The insulinotropic effect of exogenous glucagon-like peptide-1 is not affected by acute vagotomy in anaesthetized pigs.
    Veedfald S; Hansen M; Christensen LW; Larsen SA; Hjøllund KR; Plamboeck A; Hartmann B; Deacon CF; Holst JJ
    Exp Physiol; 2016 Jul; 101(7):895-912. PubMed ID: 27027735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects.
    Shah M; Franklin B; Adams-Huet B; Mitchell J; Bouza B; Dart L; Phillips M
    Eur J Nutr; 2017 Apr; 56(3):1053-1062. PubMed ID: 26759261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM; Pala L; Mannucci E
    J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal.
    Dandona P; Ghanim H; Abuaysheh S; Green K; Batra M; Dhindsa S; Makdissi A; Patel R; Chaudhuri A
    Am J Physiol Endocrinol Metab; 2015 Feb; 308(3):E185-91. PubMed ID: 25406260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.
    Zander M; Madsbad S; Deacon CF; Holst JJ
    Diabetologia; 2006 Feb; 49(2):369-74. PubMed ID: 16385384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats.
    Krieger JP; Langhans W; Lee SJ
    Physiol Behav; 2018 Aug; 192():194-199. PubMed ID: 29654813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance.
    Punjabi M; Arnold M; Rüttimann E; Graber M; Geary N; Pacheco-López G; Langhans W
    Endocrinology; 2014 May; 155(5):1690-9. PubMed ID: 24601880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia.
    Kawano T; Tanaka K; Chi H; Eguchi S; Yamazaki F; Kitamura S; Kumagai N; Yokoyama M
    Anesth Analg; 2012 Jul; 115(1):62-9. PubMed ID: 22504208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role.
    Nahmias A; Stahel P; Tian L; Xiao C; Lewis GF
    Arterioscler Thromb Vasc Biol; 2021 Jun; 41(6):1893-1900. PubMed ID: 33951941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
    Carr RD; Larsen MO; Jelic K; Lindgren O; Vikman J; Holst JJ; Deacon CF; Ahrén B
    J Clin Endocrinol Metab; 2010 Feb; 95(2):872-8. PubMed ID: 20008019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
    Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
    Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
    Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
    Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.